SNYNF (SNYNF) Stock Price & Analysis
SNYNF (SNYNF) rose 2.18% to USD 88.5 as of June 10, 2026 at 01:04 UTC, according to Nexqual real-time market data.
SNYNF last closed at USD 86.61; the session ranged USD 88.5–88.5 on volume of 100 shares. Market capitalization is $105.92B, with a 52-week range of USD 83.17–106.34 (PNK). Source: Nexqual, June 10, 2026 at 01:04 UTC.
Key Statistics (as of June 10, 2026 at 01:04 UTC)
| Price | USD 88.5 |
|---|---|
| Change | ▲ 2.18% (up) |
| Previous Close | USD 86.61 |
| Open | USD 88.5 |
| Day Range | USD 88.5 – 88.5 |
| 52-Week Range | USD 83.17 – 106.34 |
| Volume | 100 shares |
| Market Cap | $105.92B |
| Exchange | PNK |
Technical Analysis (SNYNF)
Nexqual's technical model rates SNYNF "SELL" based on 1 bullish and 4 bearish signals across 123 daily candles, as of June 10, 2026 at 01:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.82 (neutral) |
| vs SMA50 | Below (USD 90.32) |
| MACD | -0.83 (negative) |
Analyst Ratings (SNYNF)
Wall Street analysts rate SNYNF "None", per Nexqual as of June 10, 2026 at 01:04 UTC.
| Consensus Rating | None |
|---|
Earnings (SNYNF)
| Next Earnings Date | 2026-04-23 |
|---|---|
| Revenue Estimate | $11.00B |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
Financials & Fundamentals (SNYNF)
| Total Revenue | $47.35B |
|---|---|
| Revenue Growth (YoY) | +6.00% |
| Gross Margin | +72.36% |
| Operating Margin | +20.00% |
| Profit Margin | +15.95% |
| ROE | +6.58% |
| Debt / Equity | 27.37 |
| Current Ratio | 1.01 |
| Total Cash | $5.54B |
| Total Debt | $20.02B |
| Free Cash Flow | $16.67B |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
Financial Health Score (SNYNF)
Nexqual rates SNYNF's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 01:04 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 72%, operating 20% |
| Balance Sheet | Strong — $5.54B cash vs $20.0B debt |
| Cash Flow | Strong — FCF $16.7B, 38% margin |
| Efficiency | Mixed — ROE 7%, ROA 4.7% |
Ownership (SNYNF)
| Insider Ownership | +10.26% |
|---|---|
| Institutional Ownership | +42.22% |
| Shares Outstanding | 1.20B |
| Float | 1.09B |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
Leadership (SNYNF)
SNYNF is led by Belen Garijo Lopez (age 65), CEO & Director, per Nexqual as of June 10, 2026 at 01:04 UTC.
| CEO & Director | Belen Garijo Lopez (age 65) |
|---|---|
| Executive VP & CFO | François-Xavier Roger (age 63) |
| Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing | Pierre Chancel (age 68) |
| Executive Vice President of General Medicines | Olivier Charmeil (age 62) |
Major Backers & Investors (SNYNF)
Notable institutional backers of SNYNF include Goldman Sachs, Capital Income Builder, PUTNAM LARGE CAP VALUE FUND, according to Nexqual as of June 10, 2026 at 01:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Goldman Sachs | 0.84% |
| Capital Income Builder | 0.51% |
| PUTNAM LARGE CAP VALUE FUND | 0.46% |
| Fidelity | 0.34% |
| Dodge & Cox Funds-Dodge & Cox International Stock Fund | 0.33% |
| Income Fund of America | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 2.12% |
| BlackRock | 0.96% |
Source: Nexqual, June 10, 2026 at 01:04 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| GLAXF | GSK plc | USD 23.54 | ▼ 4.54% |
| NVSEF | Novartis AG | USD 148.8 | ▲ 2.71% |
| NONOF | Novo-Nordisk A/S | USD 41.6 | ▼ 4.06% |
| RHHVF | Roche Holding Ltd | USD 409 | ▼ 1.3% |
| RHHBF | Roche Holding Ltd | USD 409 | ▲ 0.22% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 01:04 UTC. This page is informational and not investment advice.